

Product Datasheet

A20/TNFAIP3 Antibody - BSA Free NBP1-77024

Unit Size: 0.1 mg

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

www.novusbio.com



technical@novusbio.com

Publications: 1

Protocols, Publications, Related Products, Reviews, Research Tools and Images at:
www.novusbio.com/NBP1-77024

Updated 3/4/2026 v.20.1

Earn rewards for product
reviews and publications.

Submit a publication at www.novusbio.com/publications

Submit a review at www.novusbio.com/reviews/destination/NBP1-77024



NBP1-77024

A20/TNFAIP3 Antibody - BSA Free


Product Information	
Unit Size	0.1 mg
Concentration	1 mg/ml
Storage	Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Clonality	Polyclonal
Preservative	0.02% Sodium Azide
Isotype	IgG
Purity	Peptide affinity purified
Buffer	PBS
Target Molecular Weight	95 kDa

Product Description	
Host	Rabbit
Gene ID	7128
Gene Symbol	TNFAIP3
Species	Human, Mouse, Rat
Immunogen	Antibody was raised against a 17 amino acid synthetic peptide near the center of human A20/TNFAIP3 . The immunogen is located within amino acids 340 - 390 of A20/TNFAIP3 Antibody. Amino Acid Squence: VQHEYKKWQENSQARR


Product Application Details	
Applications	Western Blot, Immunohistochemistry-Paraffin, ELISA, Immunocytochemistry/Immunofluorescence, Immunohistochemistry
Recommended Dilutions	Western Blot 1-2 ug/ml, ELISA 1:100-1:2000, Immunohistochemistry 5 ug/ml, Immunocytochemistry/ Immunofluorescence 20 ug/mL, Immunohistochemistry-Paraffin 5 ug/ml

Images


Western Blot: A20/TNFAIP3 Antibody [NBP1-77024] - Analysis of TNFAIP3 in Jurkat cell lysate with TNFAIP3 antibody at (A) 1 and (B) 2 ug/mL.




Immunohistochemistry-Paraffin: A20/TNFAIP3 Antibody [NBP1-77024] - Human lung tissue with TNFAIP3 antibody at 5 ug/ml.




Immunocytochemistry/ Immunofluorescence: A20/TNFAIP3 Antibody - BSA Free [NBP1-77024] - Immunofluorescence of A20/TNFAIP3 in Human Lung cells with A20/TNFAIP3 antibody at 20 ug/mL.




A20 downregulation promoted necroptosis in vitro. (A) Primary neuron and astrocyte were obtained and verified in relative antibody. (B) A20 protein expression in primary neuron, primary astrocyte and HAPI. (C) Relative mRNA expression of A20 in different cell types was obtained from a database of Stanford University (https://web.stanford.edu/group/barres_lab/brain_rnaseq.html). (D) A20 was significantly decreased after si-A20 treatment in the three cell types, including primary neuron, primary astrocyte and HAPI. (E,F) Tumor necrosis factor (TNF)- α (10 ng/ml) + Z-VAD (100 μ m) combination (TZ) as a necroptosis inducer was used for 24 h. In primary neuron, RIP1, RIP3 and MLKL were tested by western blot. Data were analyzed by statistical. (G,H) TUNEL assays and (I) CCK-8 (n = 4) were used to test cell death and viability of neuron after 24 h treatment. (J–M) Western blot assay was used to test RIP1, RIP3, MLKL, NF-KB and relative inflammatory factors in primary HAPI and astrocyte respectively. Data were measured by one way ANOVA plus Tukey's test. *P < 0.05 and **P < 0.01 vs. TZ group; #P < 0.05 and ##P < 0.01 vs. TZ+si-NC group. Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/31607859>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.




A20 downregulation promoted necroptosis in vitro. (A) Primary neuron and astrocyte were obtained and verified in relative antibody. (B) A20 protein expression in primary neuron, primary astrocyte and HAPI. (C) Relative mRNA expression of A20 in different cell types was obtained from a database of Stanford University (https://web.stanford.edu/group/barres_lab/brain_rnaseq.html). (D) A20 was significantly decreased after si-A20 treatment in the three cell types, including primary neuron, primary astrocyte and HAPI. (E,F) Tumor necrosis factor (TNF)- α (10 ng/ml) + Z-VAD (100 μ m) combination (TZ) as a necroptosis inducer was used for 24 h. In primary neuron, RIP1, RIP3 and MLKL were tested by western blot. Data were analyzed by statistical. (G,H) TUNEL assays and (I) CCK-8 (n = 4) were used to test cell death and viability of neuron after 24 h treatment. (J–M) Western blot assay was used to test RIP1, RIP3, MLKL, NF- κ B and relative inflammatory factors in primary HAPI and astrocyte respectively. Data were measured by one way ANOVA plus Tukey's test. *P < 0.05 and **P < 0.01 vs. TZ group; #P < 0.05 and ##P < 0.01 vs. TZ+si-NC group. Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/31607859>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



AAV-shA20 attenuated the anti-necroptotic roles of Nec-1 and melatonin and recovered the RAGE/NF- κ B pathway. (A,B) In the cortex tissues, AAV-shA20 inhibited the effect of Nec-1 and melatonin on RIP1, RIP3 and MLKL, determined by immunoblotting and immunohistochemistry. β -actin was used as a control. (C,D) The same results were demonstrated in hippocampal CA1 tissues. (E,F) Restored RAGE and active NF- κ B pathway were detected in cortex tissues by immunoblotting after AAV-shA20 administration. The same results were demonstrated in hippocampal CA1 tissues. β -actin was used as a control. Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/31607859>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



AAV-shA20 attenuated the anti-necroptotic roles of Nec-1 and melatonin and recovered the RAGE/NF- κ B pathway. (A,B) In the cortex tissues, AAV-shA20 inhibited the effect of Nec-1 and melatonin on RIP1, RIP3 and MLKL, determined by immunoblotting and immunohistochemistry. β -actin was used as a control. (C,D) The same results were demonstrated in hippocampal CA1 tissues. (E,F) Restored RAGE and active NF- κ B pathway were detected in cortex tissues by immunoblotting after AAV-shA20 administration. The same results were demonstrated in hippocampal CA1 tissues. β -actin was used as a control. Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/31607859>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Publications

Bao Z, Fan L, Zhao L et al. Silencing of A20 Aggravates Neuronal Death and Inflammation After Traumatic Brain Injury: A Potential Trigger of Necroptosis Front. Mol. Neurosci. 2019-09-19 [PMID: 31607859] (WB, Rat)



Novus Biologicals USA

10730 E. Briarwood Avenue
Centennial, CO 80112
USA
Phone: 303.730.1950
Toll Free: 1.888.506.6887
Fax: 303.730.1966
nb-customerservice@bio-techne.com

Bio-Techne Canada

21 Canmotor Ave
Toronto, ON M8Z 4E6
Canada
Phone: 905.827.6400
Toll Free: 855.668.8722
Fax: 905.827.6402
canada.inquires@bio-techne.com

Bio-Techne Ltd

19 Barton Lane
Abingdon Science Park
Abingdon, OX14 3NB, United Kingdom
Phone: (44) (0) 1235 529449
Free Phone: 0800 37 34 15
Fax: (44) (0) 1235 533420
info.EMEA@bio-techne.com

General Contact Information

www.novusbio.com
Technical Support: nb-technical@bio-techne.com
Orders: nb-customerservice@bio-techne.com
General: novus@novusbio.com

Products Related to NBP1-77024

NBP1-77024PEP	A20/TNFAIP3 Antibody Blocking Peptide
HAF008	Goat anti-Rabbit IgG Secondary Antibody [HRP]
NB7160	Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP]
NBP2-24891	Rabbit IgG Isotype Control

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NBP1-77024

Earn gift cards/discounts by submitting a publication using this product:
www.novusbio.com/publications

